Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



المدبربة العام

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No \$2 dated 30/4/2023 Regarding NCMDR Field Safety Corrective Action of BIOPHENTM Protein C LRT and BIOPHENTM Protein C 5 from (mfr: HYPHEN BioMed).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُـمان وزارة الـصحـة الـمـديـريـة العامـة للـصيـدلـة والــرقـابـة الـدوائـيـة مـسـقـط

Circular No. 32/2023

09 -10-1444 H

30 -04-2023

Field Safety Corrective Action of BIOPHENTM Protein C LRT and BIOPHENTM Protein C 5 from HYPHEN BioMed.

Source	NCMDR - National Center Medical Device Reporting- SFDA. https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19499
Product	BIOPHEN™ Protein C LRT and BIOPHEN™ Protein C 5.
Description	IVD.
Manufacturer	HYPHEN BioMed.
The affected products	BIOPHEN Protein C LRT Reference: 221211 Lot: FA07491F, FA18431G, F2001733, FA20041H, FA20461J Basic UDI-DI: 366353700062BB BIOPHEN Protein C 5 Reference: 221205 Lot: FA083327 Basic UDI-DI: 366353700063BD
Reason	New warnings and precautionary statements on products labelling.
Action	 Use the new IFU and SDS. Destruct the previous ones. Contact the local agent for remedial action.
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

har

Dr. Mohammed Hamdan Al Rubaje

Director General



